#152153

Anti-c-Met [12.1]

Cat. #152153

Anti-c-Met [12.1]

Cat. #: 152153

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: c-Met, cMet

Class: Monoclonal

Application: IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Julin Wong ; David Lane

Institute: University of Dundee

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-c-Met [12.1]
  • Clone: 12.1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IF ; IP ; WB
  • Description: c-Met is a tyrosine receptor kinase which is activated by its ligand, the hepatocyte growth factor. Activation of c-Met leads to a wide spectrum of biological activities such as motility, angiogenesis, morphogenesis, cell survival and cell regeneration. c-Met is abnormally activated in many tumour types. Aberrant c-Met activation was found to induce tumour development, tumour cell migration and invasion, and the worst and final step in cancer progression, metastasis.
  • Immunogen: Bacterially expressed human c-Met alpha chain
  • Isotype: IgG1 kappa
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: SNU-5, U-87MG and MKN45 cells (negative control: T47D cells)

Target Details

  • Target: c-Met, cMet
  • Tissue cell line specificity: SNU-5, U-87MG and MKN45 cells (negative control: T47D cells)
  • Target background: c-Met is a tyrosine receptor kinase which is activated by its ligand, the hepatocyte growth factor. Activation of c-Met leads to a wide spectrum of biological activities such as motility, angiogenesis, morphogenesis, cell survival and cell regeneration. c-Met is abnormally activated in many tumour types. Aberrant c-Met activation was found to induce tumour development, tumour cell migration and invasion, and the worst and final step in cancer progression, metastasis.

Applications

  • Application: IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

Related Tools

  • Related tools: Anti-c-Met 13 ; Anti-c-Met 8 ; Anti-c-Met 17

References

  • Wong et al. 2013. Oncotarget. 4(7):1019-36. PMID: 23859937.
  • Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth.